دورية أكاديمية
أعرض في EDS

Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients.

التفاصيل البيبلوغرافية
العنوان: Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients.
المؤلفون: Daly KP; Department of Cardiology, Boston Children's Hospital, Boston, MA, USA., Chandler SF, Almond CS, Singh TP, Mah H, Milford E, Matte GS, Bastardi HJ, Mayer JE, Fynn-Thompson F, Blume ED
المصدر: Pediatric transplantation [Pediatr Transplant] 2013 Nov; Vol. 17 (7), pp. 661-9. Date of Electronic Publication: 2013 Aug 06.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Munksgaard Country of Publication: Denmark NLM ID: 9802574 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1399-3046 (Electronic) Linking ISSN: 13973142 NLM ISO Abbreviation: Pediatr Transplant Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Copenhagen ; Malden, MA : Munksgaard, c1997-
مواضيع طبية MeSH: Cytotoxicity Tests, Immunologic*, Antibodies/*immunology , Graft Rejection/*immunology , Heart Transplantation/*methods, Adolescent ; Child ; Child, Preschool ; Female ; Graft Survival ; HLA Antigens/immunology ; Heart Failure/immunology ; Heart Failure/surgery ; Humans ; Immunoglobulins, Intravenous/administration & dosage ; Immunosuppressive Agents/therapeutic use ; Infant ; Male ; Retrospective Studies ; Risk Factors ; Time Factors ; Treatment Outcome
مستخلص: Sensitization to HLA is a risk factor for adverse outcomes after heart transplantation. Requiring a negative prospective CM results in longer waiting times and increased waitlist mortality. We report outcomes in a cohort of sensitized children who underwent transplant despite a positive CDC CM+ using a protocol of antibody depletion at time of transplant, followed by serial IVIG administration. All patients <21 yrs old who underwent heart transplantation at Boston Children's Hospital from 1/1998 to 1/2011 were included. We compared freedom from allograft loss, allograft rejection, and serious infection between CM+ and CM- recipients. Of 134 patients in the cohort, 33 (25%) were sensitized prior to transplantation and 12 (9%) received a CM+ heart transplant. Serious infection in the first post-transplant year was more prevalent in the CM+ patients compared with CM- patients (50% vs. 16%; p = 0.005), as was HD-AMR (50% vs. 2%; p < 0.001). There was no difference in freedom from allograft loss or any rejection. At our center, children transplanted despite a positive CM had acceptable allograft survival and risk of any rejection, but a higher risk of HD-AMR and serious infection.
(© 2013 John Wiley & Sons A/S.)
References: Circulation. 2006 May 16;113(19):2313-9. (PMID: 16702487)
Clin Transplant. 1997 Apr;11(2):134-8. (PMID: 9113450)
J Heart Lung Transplant. 2007 Aug;26(8):796-807. (PMID: 17692783)
Pediatr Transplant. 1998 May;2(2):92-105. (PMID: 10082441)
Ann Thorac Surg. 1997 Oct;64(4):1120-5. (PMID: 9354538)
Pediatr Transplant. 1997 Aug;1(1):8-21. (PMID: 10084782)
J Heart Lung Transplant. 1997 Dec;16(12):1207-16. (PMID: 9436132)
Transplantation. 1994 Feb 27;57(4):553-62. (PMID: 8116041)
Transplantation. 1992 Oct;54(4):651-5. (PMID: 1412756)
Transpl Immunol. 1993;1(1):60-5. (PMID: 8081763)
Pediatr Transplant. 2005 Apr;9(2):208-14. (PMID: 15787795)
Clin Transplant. 2006 Jul-Aug;20(4):476-84. (PMID: 16842525)
J Heart Lung Transplant. 2007 Jun;26(6):565-71. (PMID: 17543778)
Circulation. 1998 Aug 25;98(8):786-93. (PMID: 9727549)
Transplantation. 1998 Sep 27;66(6):800-5. (PMID: 9771846)
J Heart Lung Transplant. 2011 Nov;30(11):1221-7. (PMID: 21821435)
J Heart Lung Transplant. 2001 Jun;20(6):646-53. (PMID: 11404170)
Circulation. 1999 Nov 9;100(19 Suppl):II229-35. (PMID: 10567309)
J Heart Lung Transplant. 1994 Mar-Apr;13(2):194-201. (PMID: 8031799)
Circulation. 2007 Sep 11;116(11 Suppl):I172-8. (PMID: 17846300)
Circulation. 1996 Nov 1;94(9 Suppl):II294-7. (PMID: 8901763)
Transplantation. 2000 Mar 15;69(5):814-8. (PMID: 10755532)
Transplantation. 2005 Oct 27;80(8):1019-25. (PMID: 16278580)
Transpl Immunol. 2004 Jan;12(2):177-83. (PMID: 14967316)
J Heart Lung Transplant. 2007 Sep;26(9):876-82. (PMID: 17845925)
J Heart Lung Transplant. 2006 Feb;25(2):153-9. (PMID: 16446213)
J Heart Lung Transplant. 1991 Nov-Dec;10(6):921-9; discussion 929-30. (PMID: 1756157)
J Heart Lung Transplant. 2005 Nov;24(11):1710-20. (PMID: 16297770)
J Heart Lung Transplant. 1999 Jul;18(7):701-6. (PMID: 10452347)
J Heart Lung Transplant. 2013 Jan;32(1):56-62. (PMID: 23157944)
J Heart Lung Transplant. 2011 Jun;30(6):601-11. (PMID: 21555100)
J Am Soc Nephrol. 2010 Aug;21(8):1398-406. (PMID: 20634297)
Am J Transplant. 2004 Jul;4(7):1033-41. (PMID: 15196059)
معلومات مُعتمدة: K12 HD052896 United States HD NICHD NIH HHS; T32HL07572 United States HL NHLBI NIH HHS; T32 HL007572 United States HL NHLBI NIH HHS; K12HD052896-06 United States HD NICHD NIH HHS; L40 HL110356 United States HL NHLBI NIH HHS
فهرسة مساهمة: Keywords: anti-HLA antibody; antibody-mediated rejection; infectious risk; outcome; pediatric heart transplantation; plasmapheresis
المشرفين على المادة: 0 (Antibodies)
0 (HLA Antigens)
0 (Immunoglobulins, Intravenous)
0 (Immunosuppressive Agents)
تواريخ الأحداث: Date Created: 20130808 Date Completed: 20140520 Latest Revision: 20220331
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC3843490
DOI: 10.1111/petr.12131
PMID: 23919762
قاعدة البيانات: MEDLINE
الوصف
تدمد:1399-3046
DOI:10.1111/petr.12131